MEDI4736, an engineered fully-human anti-PD-L1 antibody, has been reported to have an ORR in 13% across all the patients with lung cancer, but up to 39% in PD-L1+ patients and 5% in PD-L1 negative patients [83]. The gene discussed is CD274; the disease is lung cancer.